Optimal NT-proBNP cut-off values increased progressively with advancing CKD: 694 pg/mL in Stage 3a, 1,452 pg/mL in Stage 3b, ...

Ischemic heart disease is the leading cause of disability and premature death worldwide. Chronic coronary syndrome (CCS), previously known as stable angina, is a progressive and chronic disease of the ...

MYQORZO was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms, and by the China National Medical ...

Background A 64-year-old male was observed as an outpatient with atypical, non-exercise-induced chest pain and palpitations. He had arterial hypertension and marked concentric left ventricular ...

European Commission Approval Based on Results of SEQUOIA-HCM First European Launch Expected in Germany in Q2 2026 SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorpora ...

Background Drug exposure has been reported in association with Takotsubo syndrome, but the breadth and relative strength of ...

Despite the availability of effective antihypertensive therapies, global blood pressure control rates remain unacceptably low. Contributing factors, such as low treatment adherence, therapeutic ...

Edgewise Therapeutics Inc. reports fourth-quarter results on Thursday, February 19, with investors weighing widening losses against the clinical-stage biotech’s progress toward what analysts call a ...

Cytokinetics, Incorporated CYTK announced that the European Commission (EC) has approved Myqorzo (aficamten), 5 mg, 10 mg, 15 ...

The report illustrates that myocarditis can occur without bacteraemia and may resolve with individualised non-antibiotic treatment.

Novo Nordisk advanced coramitug into the Phase III CLEOPATTRA trial, evaluating 1,280 patients with amyloid transthyretin cardiomyopathy or ATTR-CM. This decision was informed by results from their ...